Accreditation Continuing Education Program Information
The 2022 Annual Meeting, held in Denver, Colo., from May 1 - 4, is an accredited continuing education activity. Attendees who register for CME credits and pay the processing fee are eligible to claim credit for attending in-person, accredited paper and cross-sectional group sessions, minisymposia and symposia. Refer to the instructions to receive credit and/or certificates section below for full details.
The virtual Annual Meeting, May 11 - 12, is not an accredited continuing education activity. Attendees of virtual sessions are not eligible to claim CME credit.
Statement of need
Ophthalmic researchers and physicians are often unaware of and/or have limited exposure to the most recent research advances in vision and ophthalmology. This research continuously evolves toward enhancing the general understanding of the eye and visual systems, which gives rise to new pre-clinical treatment options, and revised standards of practice. Exposure to this new information is a critical first step in enhancing the understanding of basic eye functions and vision disease processes.
The educational design of this activity addresses the needs of basic researchers, clinician-scientists, ophthalmologists, ophthalmology residents, optometrists, post-doctoral fellows, graduate students, PhD candidates, medical students and research assistants/associates involved in the treatment of patients with eye and vision diseases and disorders.
After participating in this CME activity, participants should be able to:
- Discuss the results of basic and clinical ophthalmology investigations and vision research underway, relevant to my area of interest or practice.
- Describe new models and methods being used by researchers and practitioners in eye and vision science.
- Cite ways in which new research data and methods may influence my research and/or practice.
- Discuss prospective advancements in eye and vision research and/or practice.
Physician accreditation statement
The Association for Research in Vision and Ophthalmology (ARVO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician credit designation
The Association for Research in Vision and Ophthalmology designates this live activity for a maximum of 28 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
International Attendees: The American Medical Association (AMA) has determined that physicians not licensed in the U.S who participate in CME activities are eligible for AMA PRA Category 1 Credit™.
The following Annual Meeting session types are not certified as Continuing Medical Education (CME) and are not eligible for AMA PRA Category 1 Credit™: ALCON/Keynote series, Award lectures, Posters, SiGs (Special Interest Group Sessions), and Special sessions.
View the list of sessions. Accredited sessions are indicated with an asterisk in the CME column.
Instructions to receive credit and/or obtain a certificate
Attendees interested in claiming AMA PRA Category 1 Credits™ for attendance at the Annual Meeting must pay the CME credits and certificates fee. Payment is collected during the registration process by adding “CME credits and certificates” as a session. Attendees who do not register for CME before the conclusion of the meeting will not be able to claim and request credit. Attendees registered as guests are not eligible to receive CME credit. Only the sessions listed as “accredited” are eligible for credit.
CME registrants will receive an email with credit claiming instructions prior to the start of the Annual Meeting or within two business days of your purchase (whichever is later). All requests for credit must be submitted no later than 11:59pm U.S. Eastern Time on Wednesday, Aug. 31, 2022.
CME credit and certificates processing fee
|Member/Exhibitor (paid full-meeting access badge)||$99|
|Nonmember/Exhibitor (complimentary full meeting access badge only)||$119|
Certificate of participation
ARVO is accredited to offer AMA PRA Category 1 Credits™ to physicians. All other participants in the CME program may request a Certificate of Participation that documents the number of hours attended* by following the same instructions listed above and paying the CME credits and certificates fee.
*Some accrediting agencies may award equivalent Continuing Education (CE) credit when presented with a Certificate of Participation from an activity that offered AMA PRA Category 1 Credit™. Check with your accrediting agency for more information.
Certificate of attendance
Certificates of attendance are available free to all attendees. These certificates state that one has attended the Annual Meeting but does not offer credit tracking. They will be available for pick-up onsite at the meeting registration desk and ARVO Central in the exhibit hall.
American Board of Ophthalmology (ABO) diplomates
Successful completion of this CME activity, which includes participation in the evaluation component, earns credit toward the Lifelong Learning requirement for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting credit.
The Annual Meeting qualifies for Lifelong Learning (Part II). Credits will be reported to the ABO via the ACCME in September each year.
ARVO does not solicit commercial support so learner data will not be shared with any entity other than the ACCME for the purpose of granting credit. Attendees will be able to provide the required information for Continuing Certification credit tracking on the Overall Meeting Evaluating Form. By providing the required information, attendees will give ARVO permission to share their learner data with the ACCME.
Royal College of Physicians and Surgeons of Canada
Fellows and Health Care Professionals participating in the Continuing Certification Program can record credits earned at the Annual Meeting toward Section 1: Group Learning Credits.
European Union of Medical Specialists (UEMS) CME/CPD requirements
European physicians can convert the credit earned from the Annual Meeting to meet the European Union of Medical Specialists (UEMS) CME/CPD requirements.
The American Medical Association has an agreement of mutual recognition of credits with the UEMS, the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at firstname.lastname@example.org.
Association for Research in Vision and Ophthalmology
5515 Security Lane, Suite 500, Rockville, MD 20852-5007
phone: +18.104.22.16800, email: email@example.com
The Annual Meeting provides a forum for the open exchange and discussion of research results and scientific advancements in the field of ophthalmology; however, ARVO makes no representation or warranty as to the truth, originality, or accuracy of the information presented at the meeting or in materials distributed in connection with them. Nor are the views expressed by the individual speakers necessarily the views of ARVO. ARVO supports ACCME’s policy on evidence-based content and encourages faculty to adhere to these standards when planning a presentation.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this meeting is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclaimer off-label use
The Annual Meeting may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (Food and Drug Administration). ARVO does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
Disclosure of Relevant Financial Relationships.
ARVO requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose all financial relationships with any ineligible company within the last 24 months. All identified relevant financial relationships are thoroughly vetted by ARVO for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated by ARVO.
ARVO considers presenting authors, not co-authors, to be in control of the educational content. It is ARVO’s policy and traditional scientific publishing practice to acknowledge all people contributing to the research, regardless of CME control of the live presentation of that content. ARVO collects and publishes disclosures from all co-authors although they do not have control of the CME content.
Disclosure information for presenters will be provided within initial disclosure slides, prior to the start of their respective presentations.
Disclosure for all individuals involved in planning and managing this accredited CE activity are listed here with their relevant disclosure information.
The following individuals on the Annual Meeting Program Committee (AMPC) reported no relevant financial relationships:
Justine R Smith, FRANZCO, PhD, FARVO (Chair); Alison Abraham, PhD, MS, MHS; Petr Baranov MD, PhD; Alexander Black, PhD, MPH, BAppSc(Optom); Aurelie Calabrese, PhD; Andrew Carkeet, PhD; Matilda Chan, MD, PhD; Yan Chen, PhD; Catherine Cheng, PhD; Carol Cheung, PhD; Toco Chui, PhD; Abbot Clark, PhD, FARVO, FAAO; Vivien Coulson-Thomas, PhD; Catherine Cukras, MD, PhD; Steven DeVries, MD, PhD; Joshua Ehrlich, MD, MPH; Sabine Fuhrmann, PhD; Fatema Ghasia, MD; Stephanie Hagstrom, Ph.D.; Martin Heur, MD, PhD; Sudha Iyengar, PhD; Vishal Jhanji, MD, FRCS, FRCOphth; Chea-su Kee, PhD; Tiarnan Keenan, BM BCh, PhD; Vikas Khetan, DNB, FRCS Ed, FRCS; Raghu Krishnamoorthy, PhD; Ashok Kumar, PhD; Van Lansingh, MD, PhD; Julie Lim, PhD; Paloma Liton, PhD; Rajiv Mohan, PhD; Juliet Moncaster, PhD; Yuki Morizane, MD, PhD; Carlo Rivolta, PhD; Jos Rozema, PhD; Doreen Schmidl, MD, PhD; Tiffany Schmidt, PhD; Elena Semina, PhD; Anthony St. Leger, PhD; Dorota Stankowska, PhD; Daniel Sun, PhD; Budd Tucker, PhD; Roxana Ursea, MD; Ruth van Nispen, MSc, MA, PhD; Kyung Chul Yoon, MD, PhD; and Yan Zhang, PhD
The individuals on the Continuing Medical Education (CME) Committee reported no relevant financial relationships:
Sarah Zhang, MD (Chair); Ron Adelman, MD, MPH, MBA, FARVO; Mashael Al-Namaeh, OD, MS, PhD; Giulia Corradetti, MD; Haijiang Lin, MD, PhD; Sangly Srinivas, PhD
The following activity managers reported no relevant financial relationships:
Regina Borkoski; Cathy Conley; Kathy Cox; Emily Ware and Lancey Cowan, JD, CAE
The following clinical content reviewers reported no relevant financial relationships:
Katie Propst, PhD, Lindsay Scott, PT, DPT, ATC
Identified relevant financial relationships of activity planners and managers
Ineligible company (nature of the relationship)
|Jesse Berry, MD||AMPC||
Immunocore: (C); Castle Biosciences: (C); Biotissue: (C); Patent Application filed: Aqueous humor cell free DNA for diagnostic and Prognostic evaluation of Ophthalmic Disease: (P)
|Sunil Chauhan, DVM, PhD||AMPC||
Claris Biotherapeutics: (I, C, S); Aramis Biosciences: (I, C, S)
|Edward Chaum, MD, PhD||AMPC||
1-800 Contacts: (C, R); HillRom: (C, R, P)
|Alice Davidson, PhD||AMPC||
ProQR Therapeutics (Leiden, Netherlands): (F); Triplet Therapeutics (Boston, US): (C); Design Therapeutics (California, US): (C); LoQus23 Therapeutics (London, UK): (C)
|Pedram Hamrah, MD||AMPC||
Novartis: (C, F); Dompe: (F); Noveome: (F); Oysterpoint Pharma: (C, F); Okyo: (F); Coopervision: (F); Ocular Therapeutics: (F); Santen: (C); Clementia: (C); Novaliq: (C); Ocunova: (C); Sanofi: (C); Oculis: (C); Tufts Medical center: (R)
|Pirro Hysi, MD, PhD||AMPC||
Nevakar Inc.: (R); PwC: (R)
|Shizuka Koh, MD, PhD||AMPC||
Alcon: (C, R), Cooper Vision: (R), JCR: (R), Johnson & Johnson: (R), Menicon: (R), Novartis: (R), Oculus: (C, R), Otsuka: (R), Rohto: (R), Sanofi: (R), Santen: (R), SEED: (F, R), Sumitomo Dainippon Pharma: (R)
|David Krizaj, PhD||AMPC||
Asha Vision LLC: (E, P, S)
|Vivian Lee, MD||AMPC||
GSK: (C, F)
|Jason Meyer, PhD||AMPC||
Wisconsin Alumni Research Foundation: (P); Stoke Therapeutics: (C)
|Jessica Morgan, PhD||AMPC||
AGTC: (F); US Patent 8226236: (P); US Patent App. 16/389,942: (P)
|Koji Nishiguchi, MD, PhD||AMPC||
Alcon: (F, R); Takeda Pharma: (F); Bayer Pharma: (F,R); JCR Pharma: (F); Novartis: (F, R); Santen Pharma: (F,R); Kowa Pharma: (F,R); Senju Pharma: (F,R); Otsuka Pharma: (F,R); Wakamoto Pharma: (F,R); Tomei Corporation: (F); HOYA: (F); JFC Sales plan: (F); Kowaika Co. Ltd.: (F); Topcon Medical Japan: (F); Nitten Pharma: (F); Mayo: (F); AMO Japan: (F); Chugai Pharma: (R)
|Yvonne Ou, MD||AMPC||
Zordera, Inc.: (C)
|Michael Pircher, PhD||AMPC||
Imagine Eyes: (C)
|Christian Pruente, MD||AMPC||
Alcon: (C, R); Bayer: (F, C, R); Novartis: (F, C, R); Roche: (F, C, R)
|Brian Samuels, MD, PhD||AMPC||
Heidelberg Engineering Incorporated: (F)
|Rebecca Sappington, PhD||AMPC||
Immunocore: (C); Castle Biosciences: (C); Biotissue: (C); Patent Application filed: Aqueous humorScheri21! cell free DNA for diagnostic and Prognostic evaluation of Ophthalmic Disease: (P)
|Marinko Sarunic, PhD, MBA||AMPC||
Seymour Vision Inc.: (F, I)
|Alexander Schuster, MD, MSc||AMPC||
Allergan: (F); Bayer: (F); Vital: (F); Heidelberg Engineering: (F); Novartis: (F); PlusOptix: (F)
|Olaf Strauss, PhD; Univ.-Prof.||AMPC||
Bayer Germany: (F); Novartis: (F)
|Mervyn Thomas, MBChB, PhD||AMPC||
Leica Microsystem: (C)
|Fuensanta Vera-Diaz, OD, PhD||AMPC||
Nevakar: (F); Essilor International: (C); Coopervision: (C)
|Stela Vujosevic, MD, PhD, FEBO||AMPC||
Alimera: (R); Apellis: (C); Allergan: (C); Bayer: (C); Novartis: (C); Roche: (C)
|Lihteh Wu, MD||AMPC||
Bayer: (C); Quantel Medical: (C)
|Yoshiaki Yasuno, PhD||AMPC||
Topcon (F); Yokogawa (F); Nikon (F); Kao (F); Sky technology (F); Tomey Corp. (P)
|Gui-shuang Ying, PhD||AMPC||
Chengdu Kanghong Biotech Ltd.: (C), Ziemer Ophthalmic Systems AG: (C) Synergy Research Inc.: (C)
|Glenn Yiu, MD, PhD||AMPC||
Alimera: (C); Allergan: (C); Carl Zeiss Meditec: (C); Clearside Biomedical: (C, R); Genentech: (C); Gyroscope Therapeutics: (C); NGM Biopharmaceutical: (C); Intergalactic Therapeutics: (C); Iridex: (C, R); Regeneron: (C); Topcon: (C); Verily: (C)
|Patrick Yu-Wai-Man, BMedSci, MBBS, PhD, FRCOphth, FRCPath||AMPC||
Chiesi: (C); GenSight Biologics: (C); PYC Therapeutics: (C)
|Thomas Ach, MD||CME||
Roche: (C); Novartis; (F, R); Nidek: (R); Heidelberg Engineering: (R); MacRegen: (I)
|Natasha Kolomeyer, MD||CME||
Allergan: (F); Abbvie: (F); Guardion Health Services Inc.: (F); Equinox: (F); Nicox: (F); Olleyes: (F); Santen: (F); Diopsys: (F); Aerie Pharmaceuticals: (F); Glaukos: (F)
Eyenovia: (C), Twenty Twenty: (C), Skye Biosciences: (C)
|Yannis Paulus, MD||CME||
PhotoSonoX LLC.: (P, E, S); Hedgefog Research Inc.: (R)
|Edmund Tsui, MD||CME||
Cylite Pty Ltd: (F); Kowa Company Ltd: (F)
|Jia Yin, MD PhD MPH||CME||
Kera Therapeutics: (I)
|Laura Lanford||Activity Manager||
Johnson & Johnson: (I); Pfizer: (I)
Financial Relationship Disclosure Code Definitions
C (Consultant/Contractor) Indicates you are a consultant or independent contractor (including contracted research) for an ACCME-defined ineligible company.
E (Employment) Indicates you are an employee of an ACCME-defined ineligible company.
F (Financial Support) Indicates financial support received from an ACCME-defined ineligible company, in the form of research funding (even if the institution receives the research grant and manages the funds), grants, research materials or in-kind services (e.g., sample analysis).
I (Personal Financial Interest) Indicates you are an investor in a company or competing company, including an ACCME-defined ineligible company, other than through a mutual or retirement fund.
N (No Financial Relationship) Indicates there is no financial relationship to disclose.
O (Owner/Co-Owner/Founder/Co-Founder) Indicates you are an owner, co-owner, founder and/or co-founder of an ACCME-defined ineligible company.
P (Patent) Indicates you are an inventor/developer designated on a patent, patent application, copyright, or trade secret, whether the patent, copyright, etc. is presently licensed or otherwise commercialized, or could be in competition with the technology described.
R (Recipient) Indicates you have received gifts, honoraria, travel reimbursement, patent royalties, or any other financial compensation in any amount from an ACCME-defined ineligible company.
S (non-remunerative) Indicates you have position(s) of influence such as officer, board member, trustee, spokesperson, etc.